Outcome of adalimumab monotherapy in paediatric non-infectious uveitis.
D A Al-JulandaniNarendra Kumar BagriN TsangSarah L N ClarkeAshish Datt UpadhyayC GulyA V RamananPublished in: Pediatric rheumatology online journal (2023)
Continuation of adalimumab monotherapy is an effective therapeutic option for the treatment of non-infectious uveitis in children who are intolerant to the combination of adalimumab and methotrexate or mycophenolate mofetil.
Keyphrases
- juvenile idiopathic arthritis
- combination therapy
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- open label
- intensive care unit
- young adults
- emergency department
- high dose
- hidradenitis suppurativa
- ulcerative colitis
- systemic lupus erythematosus
- randomized controlled trial
- clinical trial
- low dose
- replacement therapy